Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$39.53 USD
+0.04 (0.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $39.53 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
MIRM 39.53 +0.04(0.10%)
Will MIRM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIRM
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Other News for MIRM
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
Buy Rating Upheld for Mirum Pharmaceuticals as Chenodiol Nears FDA Approval and Market Exclusivity
Optimistic Outlook for Mirum Pharmaceuticals: A Strong Buy Recommendation Based on Chenodal’s NDA and Market Exclusivity Prospects